Tower Research Capital (TRC)’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Tower Research Capital (TRC)’s Portfolio NVLN Stock Details NVLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-500	Closed	-$1K	–	4681
2019 Q1	$1K	Buy	+500	New	+$569	﹤0.01%	3703
2018 Q3	–	Sell	-1,661	Closed	-$6K	–	4519
2018 Q2	$6K	Buy	1,661 +427	+35%	+$1.72K	﹤0.01%	3035
2018 Q1	$4K	Sell	1,234 -7,756	-86%	-$32.9K	﹤0.01%	2826
2017 Q4	$28K	Buy	8,990 +5,734	+176%	+$27.6K	﹤0.01%	1816
2017 Q3	$23K	Buy	3,256 +2,956	+985%	+$23.7K	﹤0.01%	2664
2017 Q2	$3K	Sell	300 -600	-67%	-$5.78K	﹤0.01%	2284
2017 Q1	$10K	Buy	900 +472	+110%	+$4.82K	﹤0.01%	1808
2016 Q4	$3K	Buy	+428	New	+$3.79K	﹤0.01%	3337

Other funds holding NVLN

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Healthcare Value Capital Woodcliff Lake, New Jersey $38.5M AUM 24.72% 1-Year Est. Return

Highbridge Capital Management New York $1.58B AUM 31.19% 1-Year Est. Return

Stonepine Capital Management Bend, Oregon $114M AUM 77.6% 1-Year Est. Return

Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return

David M. Knott $264M AUM 59.23% 1-Year Est. Return

Citadel Advisors

Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return

Geode Capital Management

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Group One Trading

Group One Trading Chicago, Illinois $3.03B AUM 104.56% 1-Year Est. Return

Franklin Street Advisors Chapel Hill, North Carolina $1.79B AUM 28.1% 1-Year Est. Return